Blood Tests and Brain Scans and Biomarkers, Oh My! How Biomarkers are Changing Alzheimer’s Disease Clinical Trials

In recent years, the U.S. Food and Drug Administration (FDA) has approved new biomarker tools for Alzheimer’s disease, including blood tests and tracers for brain scans. How are these tools used in research to help develop new Alzheimer’s treatments? Dr. Henrik Zetterberg returns to the podcast to discuss how blood tests, brain scans and other biomarker developments are transforming clinical trials and treatments for Alzheimer’s disease and other neurodegenerative conditions ahead of his upcoming Healthy Living with Mild Cognitive Impairment (MCI) event.

Guest: Henrik Zetterberg, MD, PhD, professor of neurochemistry, University of Gothenburg, visiting professor, University of Wisconsin−Madison and University College London, Biomarker Core leader, Wisconsin Alzheimer’s Disease Research Center

Show Notes

Register and learn more about the upcoming Healthy Living with MCI event featuring Dr. Zetterberg, happening on September 11, 2026, and future programs on our website.

Register and learn more about the upcoming Fall Community Conversation, happening on September 29, 2026, on our website.

Listen to our past episodes with Dr. Zetterberg, “Addressing Cochrane’s Review on Amyloid-Targeting Treatments for Alzheimer’s Disease” and “The Future of Fluid Biomarkers for Alzheimer’s Disease and Related Dementias,” on our website.

Learn more about LATE, mentioned by Dr. Zetterberg at 24:05, by listening to our episode “LATE, Explained” on our website.

Read more about the Alzheimer’s disease blood tests recently approved by the U.S. FDA on our website.

Connect with us

Find transcripts and more at our website.

Email Dementia Matters: dementiamatters@medicine.wisc.edu

Follow us on Facebook, Instagram and Twitter.